Skip to main
SGMT
SGMT logo

SGMT Stock Forecast & Price Target

SGMT Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Sagimet Biosciences is demonstrating promising developments in its clinical-stage pipeline, particularly with its lead candidate, denifanstat, which has shown significant anti-fibrotic effects in patients with nonalcoholic steatohepatitis (NASH) and has been associated with improvements in cardiovascular health markers. The recent clearance of the IND application for Sagimet's second FASN inhibitor, TVB-3567, further highlights the potential for diversification in treating dermatological conditions such as acne, reinforcing investor confidence in the company's innovative therapeutics. Additionally, positive interim data from ongoing trials underscore the effectiveness of denifanstat in improving crucial liver parameters, suggesting a strong position for future commercialization and revenue generation.

Bears say

Sagimet Biosciences Inc reported a net loss of $16.2 million for the fourth quarter of 2024, with a loss per share of $0.50, highlighting the ongoing financial struggles faced by the company. The investment outlook is marred by significant risks including the potential for disappointing Phase 3 trial results for its lead drug candidate, denifanstat, and challenges in securing regulatory approval in the U.S. Additionally, concerns about a smaller than expected commercial market opportunity, development delays, and funding capabilities further contribute to a negative sentiment toward the stock.

SGMT has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sagimet Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sagimet Biosciences Inc (SGMT) Forecast

Analysts have given SGMT a Strong Buy based on their latest research and market trends.

According to 2 analysts, SGMT has a Strong Buy consensus rating as of Aug 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sagimet Biosciences Inc (SGMT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.